Evidence map›Paper›PMID 30269924›Full record

Trial reportOphthalmology2019

Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial.

Jennifer E Thorne, Elizabeth A Sugar, Janet T Holbrook, Alyce E Burke, Michael M Altaweel, Albert T Vitale, Nisha R Acharya, John H Kempen, Douglas A Jabs, Multicenter Uveitis Steroid Treatment Trial Research Group

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02374060 (PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial), which is not on this map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02374060 phase3completednot on this map

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

TypeinterventionalSponsorJHSPH Center for Clinical TrialsRan2015 to 2018Enrolled192ConditionsMacular Edema, UveitisArmsPeriocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Adalimumab biosimilars compared to originator: impact on uveitic macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jennifer E ThorneDepartment of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Center for Clinical Trials and Data Synthesis, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: jthorne@jhmi.edu.
Elizabeth A SugarCenter for Clinical Trials and Data Synthesis, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Center for Clinical Trials and Data Synthesis, Department of Biostatistics, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
Janet T HolbrookCenter for Clinical Trials and Data Synthesis, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
Alyce E BurkeCenter for Clinical Trials and Data Synthesis, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
Michael M AltaweelThe Fundus Photograph Reading Center, Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Albert T VitaleDepartment of Ophthalmology, University of Utah, Salt Lake City, Utah.
Nisha R AcharyaDepartment of Ophthalmology, University of California, San Francisco, San Francisco, California; Department of Epidemiology, University of California, San Francisco, San Francisco, California.
John H KempenDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Eye Unit, MyungSung Christian Medical Center and MyungSung Medical School, Addis Ababa, Ethiopia.
Douglas A JabsCenter for Clinical Trials and Data Synthesis, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York.
Multicenter Uveitis Steroid Treatment Trial Research Group
Johns Hopkins University · USMassachusetts Eye and Ear Infirmary · USUniversity of California, San Francisco · USUniversity of Utah · US

Funding

ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) TrialUG1EY028091 · NEI · JOHNS HOPKINS UNIVERSITY · PI HOLBROOK, JANET T., SUGAR, ELIZABETH ANN · 2018 to 2022
$9.0M
Macular Edema Treatment Trials Associated with MUST (META-MUST)U10EY024527 · NEI · JOHNS HOPKINS UNIVERSITY · PI HOLBROOK, JANET T. · 2014 to 2019
$8.3M
MACULAR EDEMA TREATMENT TRIALS ASSOCIATED WITH MUST (META-MUST)U10EY024526 · NEI · JOHNS HOPKINS UNIVERSITY · PI JABS, DOUGLAS A · 2014 to 2018
$1.9M
Macular Edema Treatment Trials Associated with MUST (META-MUST)U10EY024531 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI ALTAWEEL, MICHAEL M · 2014 to 2018
$1.1M
NEI NIH HHS U10 EY024526NEI NIH HHS U10 EY024527NEI NIH HHS U10 EY024531NEI NIH HHS UG1 EY028091
6 · The paper itself

Abstract

purposeTo evaluate the comparative effectiveness of 3 regional corticosteroid injections for uveitic macular edema (ME): periocular triamcinolone acetonide (PTA), intravitreal triamcinolone acetonide (ITA), and the intravitreal dexamethasone implant (IDI).

designMulticenter, randomized clinical trial.

participantsPatients with uveitic ME.

methodsPatients were randomized 1:1:1 to receive 1 of the 3 therapies. Patients with bilateral ME were assigned the same treatment for both eyes.

main outcome measuresThe primary outcome was the proportion of baseline (PropBL) central subfield thickness (CST) at 8 weeks (CST at 8 weeks/CST at baseline) assessed with OCT by masked readers. Secondary outcomes included ≥20% improvement and resolution of ME, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) events over 24 weeks.

resultsAll treatment groups demonstrated improved CST during follow-up. At 8 weeks, each group had clinically meaningful reductions in CST relative to baseline (PropBL: 0.77, 0.61, and 0.54, respectively, which translates to reductions of 23%, 39%, and 46% for PTA, ITA, and IDI, respectively). Intravitreal triamcinolone acetonide (PropBL ITA/PropBL PTA, hazard ratio [HR], 0.79; 99.87% confidence interval [CI], 0.65-0.96) and IDI (PropBL IDI/PropBL PTA, HR, 0.69; 99.87% CI, 0.56-0.86) had larger reductions in CST than PTA (P < 0.0001). Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks (PropBL IDI/PropBL ITA, HR, 0.88; 99.87% CI, 0.71-1.08). Both ITA and IDI treatments also were superior to PTA treatment in improving and resolving uveitic ME. All treatment groups demonstrated BCVA improvement throughout follow-up. Both ITA and IDI groups had improvements in BCVA that was 5 letters greater than in the PTA group at 8 weeks (P < 0.004). The risk of having IOP ≥24 mmHg was higher in the intravitreal treatment groups compared with the periocular group (HR, 1.83; 95% CI, 0.91-3.65 and HR, 2.52; 95% CI, 1.29-4.91 for ITA and IDI, respectively); however, there was no significant difference between the 2 intravitreal treatment groups.

conclusionsIntravitreal triamcinolone acetonide and the IDI were superior to PTA for treating uveitic ME with modest increases in the risk of IOP elevation. This risk did not differ significantly between intravitreal treatments.

Indexed as

AdolescentAdultAgedAged, 80 and overDexamethasoneDrug Administration RoutesDrug ImplantsFemaleFollow-Up StudiesGlucocorticoidsHumansIntravitreal InjectionsMacular EdemaMaleMiddle AgedRetrospective StudiesDexamethasoneDrug ImplantsGlucocorticoidsTriamcinolone Acetonide

Identifiers

PMID30269924
PMCPMC6348060
OpenAlexW2894090142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.